Expert Opinion on Biological Therapy,
Год журнала:
2024,
Номер
24(11), С. 1261 - 1269
Опубликована: Окт. 21, 2024
Introduction
Alzheimer's
disease
can
cause
dementia
through
brain
matter
degradation.
This
study
investigates
the
monoclonal
antibody
usage
for
AD
treatment,
following
PRISMA
2020
guidelines,
and
aims
to
discern
that
offers
optimal
balance
of
efficacy
safety
individuals
with
AD.
Brain,
Год журнала:
2023,
Номер
146(10), С. 3969 - 3990
Опубликована: Май 15, 2023
Results
from
recent
clinical
trials
of
antibodies
that
target
amyloid-β
(Aβ)
for
Alzheimer's
disease
have
created
excitement
and
been
heralded
as
corroboration
the
amyloid
cascade
hypothesis.
However,
while
Aβ
may
contribute
to
disease,
genetic,
clinical,
imaging
biochemical
data
suggest
a
more
complex
aetiology.
Here
we
review
history
weaknesses
hypothesis
in
view
new
evidence
obtained
anti-amyloid
antibodies.
These
indicate
treatments
either
no
or
uncertain
effect
on
cognition.
Despite
importance
definition
argue
point
playing
minor
aetiological
role.
We
also
discuss
suggesting
concerted
activity
many
pathogenic
factors
propose
evolving
multi-factor
models
will
better
underpin
search
effective
strategies
treat
disease.
Abstract
Alzheimer’s
disease
(AD),
the
leading
cause
of
dementia,
is
characterized
by
accumulation
amyloid
plaques
and
neurofibrillary
tangles
in
brain.
This
condition
casts
a
significant
shadow
on
global
health
due
to
its
complex
multifactorial
nature.
In
addition
genetic
predispositions,
development
AD
influenced
myriad
risk
factors,
including
aging,
systemic
inflammation,
chronic
conditions,
lifestyle,
environmental
exposures.
Recent
advancements
understanding
pathophysiology
are
paving
way
for
enhanced
diagnostic
techniques,
improved
assessment,
potentially
effective
prevention
strategies.
These
discoveries
crucial
quest
unravel
complexities
AD,
offering
beacon
hope
management
treatment
options
millions
affected
this
debilitating
disease.
Brain Communications,
Год журнала:
2023,
Номер
5(3)
Опубликована: Янв. 1, 2023
Abstract
The
clinical
benefit
associated
with
anti-amyloid
immunotherapies,
a
new
class
of
drugs
for
the
treatment
Alzheimer’s
disease,
is
predicated
on
their
ability
to
modify
disease
course
by
lowering
brain
amyloid
levels.
At
time
writing,
two
amyloid-lowering
antibodies,
aducanumab
and
lecanemab,
have
obtained
United
States
Food
Drug
Administration
accelerated
approval,
further
agents
this
in
pipeline.
Based
limited
published
trial
data
date,
regulators,
payors
physicians
will
need
assess
efficacy,
effectiveness
safety,
as
well
cost
accessibility.
We
propose
that
attention
three
important
questions
related
safety
should
guide
evidence-based
consideration
drugs.
These
are:
(1)
Were
statistical
analyses
appropriate
did
they
convincingly
support
claims
efficacy?
(2)
Do
reported
effects
outweigh
concerns
are
generalizable
representative
population
people
disease?
(3)
demonstrate
modification,
suggesting
increasing
benefits
beyond
duration
trials
likely?
suggest
specific
approaches
interpreting
results
these
highlight
areas
uncertainty
where
additional
cautious
interpretation
existing
warranted.
Safe,
effective
accessible
treatments
eagerly
awaited
millions
patients
caregivers
worldwide.
While
amyloid-targeting
immunotherapies
may
be
promising
disease-modifying
treatments,
rigorous
unbiased
assessment
critical
regulatory
decision-making
subsequently
determining
provision
utility
routine
practice.
Our
recommendations
provide
framework
appraisal
payors,
patients.
The Lancet Regional Health - Americas,
Год журнала:
2023,
Номер
20, С. 100467 - 100467
Опубликована: Март 1, 2023
In
2021,
the
US
Food
and
Drug
Administration
(FDA)
granted
approval
to
aducanumab,
an
antiamyloid
antibody
for
early-stage
Alzheimer's
disease,
despite
a
lack
of
clear
clinical
evidence
demonstrating
drug's
cognitive
benefits.
The
manufacturer
initially
priced
drug
at
staggering
$56,000
per
year,
price
that
was
later
reduced
$28,200.
Unfortunately,
these
costs
do
not
include
additional
expenses
associated
with
monitoring
treatment.
However,
Centers
Medicare
Medicaid
Services
(CMS)
recently
announced
they
will
only
cover
individuals
enrolled
in
trials
limit
coverage
future
antibodies.
This
discrepancy
between
FDA
CMS
positions
has
caused
confusion
concerns
patients
who
could
potentially
benefit
from
therapy.
It
is
important
acknowledge
economic
uncertainties
surrounding
aducanumab
its
potential
impacts
on
development
processes.
FDA's
approval,
limited
evidence,
raises
questions
about
integrity
rigor
process.
high
cost
also
accessibility
concerns,
especially
those
without
insurance
or
sufficient
financial
resources.
Given
CMS's
policy,
it's
critical
evaluate
long-term
implications
this
decision
development.
Without
adequate
support
providers,
treatments
may
be
hindered.
summary,
pricing
coupled
created
confusing
concerning
landscape
patients.
It's
stakeholders,
including
patients,
clinicians,
insurers,
regulatory
bodies,
work
together
address
challenges
ensure
have
access
effective,
affordable
treatments.
Alzheimer s & Dementia,
Год журнала:
2023,
Номер
20(2), С. 1284 - 1297
Опубликована: Ноя. 20, 2023
Blood
biomarkers
have
proven
useful
in
Alzheimer's
disease
(AD)
research.
However,
little
is
known
about
their
biological
variation
(BV),
which
improves
the
interpretation
of
individual-level
data.
Bioengineering,
Год журнала:
2023,
Номер
10(2), С. 253 - 253
Опубликована: Фев. 15, 2023
As
the
most
common
form
of
dementia
and
a
progressive
neurodegenerative
disorder,
Alzheimer’s
disease
(AD)
affects
over
10%
world
population
with
age
65
older.
The
is
neuropathologically
associated
loss
neurons
synapses
in
specific
brain
regions,
deposition
amyloid
plaques
neurofibrillary
tangles,
neuroinflammation,
blood–brain
barrier
(BBB)
breakdown,
mitochondrial
dysfunction,
oxidative
stress.
Despite
intensive
effort,
there
still
no
cure
for
disorder.
Stem
cell-derived
exosomes
hold
great
promise
treating
various
diseases,
including
AD,
as
they
contain
variety
anti-apoptotic,
anti-inflammatory,
antioxidant
components.
Moreover,
stem
also
promote
neurogenesis
angiogenesis
can
repair
damaged
BBB.
In
this
review,
we
will
first
outline
major
neuropathological
features
AD;
subsequently,
discussion
cells,
cell-secreted
exosomes,
exosome
isolation
methods
follow.
We
then
summarize
recent
data
involving
use
mesenchymal
cell-
or
neural
AD.
Finally,
briefly
discuss
challenges,
perspectives,
clinical
trials
using
AD
therapy.